ACAD

ACADIA Pharmaceuticals Inc.

Price

$22.02

return (12m)

p/e

11.55

p/bv

3.48

DIVIDEND YIELD

0.00%

ACAD price

ACADIA Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ACAD

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals ACAD

Valuation

P/E

11.55

Sector -4.15

Industry -4.15

P/BV

3.48

Sector 2.06

Industry 2.06

P/Revenue (PSR)

3.96

Sector -4.16

Industry -4.16

EV/EBITDA

-2,153.41

Sector -241.86

Industry -241.86

EV/EBIT

-755.09

Sector -671.75

Industry -671.75

P/EBITDA

46.81

Sector -4.30

Industry -4.30

P/EBIT

53.65

Sector -4.35

Industry -4.35

P/Total Assets

2.70

Sector 1.46

Industry 1.46

P/Net Current Assets

5.87

Sector -12.67

Industry -12.67

P/Working Capital

5.49

Sector -12.58

Industry -12.58

EPS

2.20

Sector -2.19

Industry -2.19

BVPS

7.30

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

91.47%

Sector 36.44%

Industry 36.44%

EBITDA Margin

-0.60%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

-1.72%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

7.39%

Sector -38.78%

Industry -38.78%

Net Profit Margins

34.30%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

30.10%

Sector -67.01%

Industry -67.01%

ROA

23.40%

Sector -66.28%

Industry -66.28%

ROIC

-3.03%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.59

Sector 2.90

Industry 2.90

Net Debt / EBITDA

525.59

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

184.30

Sector -3.79

Industry -3.79

Net Debt / Equity

-0.68

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.78

Sector 0.42

Industry 0.42

Liabilities/Assets

0.22

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

17.74%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF ACADIA Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$22.02

Fair Value

$19.01

Upside Return potential.

-13.67%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ACAD

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ACAD Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

33 years

Founded: 1993

2004

Time since IPO - 22 years

601

Employees

ACADIA Pharmaceuticals Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $4.34 billion, with shareholders equity totaling $1.25 billion.

The company employs approximately 601 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, ACADIA Pharmaceuticals Inc. reported $1.10 billion in revenue, generating net income of $375.66 million.

Key financial metrics include a P/E ratio of 11.55, a price-to-book (P/B) ratio of 3.48, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ACAD.

Market cap

$4.34 billion

Net worth

$1.25 billion

$1,248,070,000.00

Assets

$1.61 billion

$1,605,230,000.00

Total Shares Outstanding

171.00 million

171,000,000

Average Daily Trading Volume

$1.67 million

$1,672,644.00

Sector

Healthcare

Industry

Biotecnologia

ACAD

ACAD revenue and profits

Financial Results ACAD

DRAG THE FRAME TO SEE MORE DATA

ACAD cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14